Systemic-onset juvenile idiopathic arthritis

Area of Science:

• Immunology
• Pediatrics
• Rheumatology

Background:

• Systemic-onset juvenile idiopathic arthritis (SoJIA) is currently classified under juvenile idiopathic arthritis (JIA).
• Systemic inflammation in SoJIA is linked to innate immune dysregulation, suggesting a potential classification within autoinflammatory disorders.
• SoJIA exhibits distinct clinical features, prognosis, and treatment responses compared to other JIA categories.

Purpose of the Study:

• To explore the classification of SoJIA within the spectrum of autoinflammatory disorders.
• To highlight the unique characteristics of SoJIA compared to other JIA categories.
• To discuss recent advances in understanding SoJIA pathogenesis and treatment.

Main Methods:

• Review of existing literature on SoJIA pathogenesis and clinical manifestations.
• Analysis of the role of IL-1 and IL-6 in SoJIA.
• Evaluation of treatment outcomes with IL-1 and IL-6 inhibitors.

Main Results:

• SoJIA shares characteristics with autoinflammatory diseases due to innate immune system involvement.
• Key clinical features include fever, lymphadenopathy, arthritis, rash, and serositis.
• IL-1 and IL-6 are pivotal in SoJIA pathogenesis, with inhibitors showing high efficacy.

Conclusions:

• SoJIA may represent a distinct entity within or alongside autoinflammatory disorders.
• Effective treatment with IL-1 and IL-6 inhibitors has significantly improved prognosis.
• Despite advances, complications like macrophage activation syndrome and long-term damage remain critical concerns.